Recent

% | $
Quotes you view appear here for quick access.

Ligand Pharmaceuticals Incorporated Message Board

stock_munching_2004 3 posts  |  Last Activity: Jun 27, 2016 1:00 PM Member since: Nov 5, 2005
SortNewest  |  Oldest  |  Highest Rated Expand all messages
  • stock_munching_2004 by stock_munching_2004 Jun 13, 2016 8:17 AM Flag

    Could be a good time for launching a replacement, like the Sumatriptan VIBEX® auto injector..
    ---
    Teva Pharmaceutical Industries, Ltd. (NYSE and TASE:TEVA) announced today that it will voluntarily suspend sales, marketing and distribution of ZECUITY® (sumatriptan iontophoretic transdermal system). Teva has received post-marketing reports of application site reactions described as burns and scars in patients treated with ZECUITY, and is working in full cooperation with the U. S. Food and Drug Administration (FDA) to better understand these adverse events. In addition to this voluntary suspension, Teva has initiated a pharmacy-level recall of the product.

    GLTA -SM2004

    Sentiment: Strong Buy

  • stock_munching_2004 by stock_munching_2004 Jun 23, 2016 8:45 AM Flag

    Takeaway message: "The settlement allows Teva to commercialize its generic version of BYETTA in the U.S. beginning October 15, 2017 or earlier under certain circumstances."
    ===

    Teva settles patent litigation with AstraZeneca, enters into license agreement Teva Pharmaceuticals USA (TEVA) announced that it has settled the patent litigation with AstraZeneca Pharmaceuticals LP (AZN), AstraZeneca AB and Amylin Pharmaceuticals, LLC (AMLN) relating to AstraZeneca's US Patent Nos. 6,858,576, 6,872,700, 6,956,026, 7,297,761, 6,902,744, 7,521,423, and 7,741,269 and AstraZeneca's BYETTA, and entered into a settlement and license agreement with AstraZeneca, pursuant to which AstraZeneca granted a license to Teva to manufacture and commercialize the generic version of BYETTA described in Teva's ANDA No. 205984 in the United States. The settlement allows Teva to commercialize its generic version of BYETTA in the U.S. beginning October 15, 2017 or earlier under certain circumstances. All other terms of the agreement are confidential. BYETTA is an injectable product used to treat type 2 diabetes. Teva remains committed to strengthening its presence in its generic injectable business globally. Teva continues investment in new, and higher-value generic injectable products. With approximately 370 generic medicines available, Teva has the largest portfolio of FDA-approved generic products and continues to bring new products to market for the patients who need them.

    Read more at:
    http://thefly.com/landingPageNews.php?id=2392108

    Sentiment: Strong Buy

  • stock_munching_2004 stock_munching_2004 Jun 27, 2016 1:00 PM Flag

    Could be they can now justify a buyout of ATRS for its injector technology and pipeline as bonus.

    GLTA -SM2004

    Sentiment: Strong Buy

LGND
103.65+1.25(+1.22%)Aug 25 4:00 PMEDT